We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CV Risk Warning Ordered for Prostate Cancer Drug Labels
CV Risk Warning Ordered for Prostate Cancer Drug Labels
October 22, 2010
The FDA Wednesday asked drugmakers to add new warnings to labeling on potential cardiovascular (CV) risks for a class of prostate cancer drugs.